Invitrogen™ Endothelial Injury Marker 12-Plex Human ProcartaPlex™ Panel

Invitrogen™ Endothelial Injury Marker 12-Plex Human ProcartaPlex™ Panel

The Human Endothelial Injury Marker 12-Plex ProcartaPlex Panel enables research in the area of vascular endothelial cell injury and regeneration by looking at 12 protein targets in a single well using Luminex xMAP technology. Simultaneous detection of these targets can help researchers explore diseases that are characterized by vascular injury, such as cardiovascular disease, atherosclerosis, peripheral vascular disease, and inflammatory processes involving endothelial cells. In addition, endothelial dysfunction is described as an extrapulmonary manifestation of SARS-CoV-2 virus infection, so researchers are also focusing on COVID-19 and post-COVID-19 syndrome or long COVID in the context of a vascular disease.

The panel is provided in a ready-to-use format with individual vials of capture and detection reagents including 1X bead mix and detection antibody mix requiring less pipetting and experimental setup. Therefore, it is not combinable with Simplex kits or other ProcartaPlex panels.The following panels are complementary to this panel, with additional protein targets relevant in this research area: Angiogenesis Panel 1 (Cat. No. EPX180-15806-901), and Atherosclerosis Panel 1 (Cat. No. EPX090-15822-901).
In addition, targets relevant in vascular injury research requiring sample pre-dilution (1:100) are combined in Angiogenesis Panel 2 (Cat. No. EPX030-15807-901) and Atherosclerosis Panel 2 (Cat. No. EPX040-15824-901). Targets included in Simplex kits or combined in a custom panel are endoglin, sICAM-1, sVCAM-1, VE-cadherin.
ProcartaPlex pre-configured panels are extensively tested for analyte combinability, interference, and cross-reactivity to provide the highest level of validation and precision. All ProcartaPlex panels are supplied with the necessary reagents to perform the assay.

The Luminex MagPlex superparamagnetic microsphere beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create 100 spectrally unique signatures that can be identified by the Luminex xMAP detection systems (Luminex 200, FLEXMAP 3D, and MAGPIX systems). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.

Target list [bead region]:

• E-selectin [77], P-selectin [55], VEGF-A [78], VEGF-D [53], PECAM-1 [72], Angiopoietin-1 [13], Syndecan-1 [14], VEGF-R2 [18], VEGF-R3 [57], MMP-1 [64], Thrombomodulin (TM) [73], VLA-4 [42]
   

Features

• Reproducible, reliable results—validated as a panel to the highest industry standard, including protein target combinability and cross-reactivity testing
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 µL sample
• Well-established Luminex technology highly referenced multiplexing platform for protein detection and quantitation

Contents

• 2 vials Human Standard Mix 14 (lyophilized)
• 1 vials Capture Bead Mix (1X)
• 1 vial Biotinylated Detection Antibody Mix (1X)
• 1 bottle Reading Buffer (1X)
• 1 bottle Wash Buffer (10X)
• 1 bottle Streptavidin-PE (1X)
• 1 bottle Universal Assay Buffer (1X)
• 8-tube strip
• Adhesive film
• Flat-bottom 96-well plate, black